Postoperative Pain Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, and Pipeline Analysis

DelveInsight's, "Postoperative Pain - Pipeline Insight, 2025" report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in Postoperative Pain pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Postoperative Pain Pipeline constitutes 45+ key companies continuously working towards developing 50+ Postoperative Pain treatment therapies, analyzes DelveInsight.

Postoperative Pain Overview:

Postoperative or postsurgical pain is defined as pain persisting for more than 3 to 6 months after surgery, differing in nature and location from any pre-surgical pain. It is often associated with neuropathic pain caused by surgical injury to major peripheral nerves. While any surgery can result in persistent postoperative pain (PPP), procedures like inguinal hernia repair and thoracic surgery, leg amputation, and coronary artery bypass surgery are at higher risk due to potential nerve damage. Surgical techniques that minimize nerve injury are critical to reducing this risk. Postoperative pain is categorized as acute (up to 7 days post-surgery) or chronic (lasting over 3 months), arising from cutaneous, deep somatic, or visceral structures.

"Postoperative Pain Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Postoperative Pain Therapeutics Market.

Request for a sample report @ https://www.delveinsight.com/report-store/postoperative-pain-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Key Takeaways from the Postoperative Pain Pipeline Report

*
DelveInsight's Postoperative Pain pipeline report depicts a robust space with 45+ active players working to develop 50+ pipeline therapies for Postoperative Pain treatment.

*
In August 2024, Mylan Specialty, LP announced that MR-107A-02 is being evaluated for its safety and efficacy in treating acute pain following herniorrhaphy.

*
In August 2024, Jiangsu HengRui Medicine Co., Ltd. disclosed an ongoing study to assess the safety and effectiveness of bupivacaine liposome injection for local infiltration analgesia in pediatric orthopedic surgeries under real-world conditions.

*
In June 2024, Johnson & Johnson Consumer Inc. announced a study aimed at determining the effectiveness of a fixed-dose combination of acetaminophen and naproxen sodium compared to a placebo in reducing pain over a 48-hour period through multiple doses.

*
In March 2024, Formosa Pharmaceuticals and AimMax Therapeutics received FDA approval for clobetasol propionate ophthalmic suspension 0.05% (APP13007) to treat postoperative inflammation and pain after ocular surgery.

*
Key Postoperative Pain companies such as Vivozon Pharmaceutical Inc., LipoCure, InSitu Biologics, and others are evaluating new drugs for Postoperative Pain to improve the treatment landscape.

*
Promising Postoperative Pain pipeline therapies in various stages of development include VVZ-149, LC-400, INSB-200, and others.

Postoperative Pain Pipeline Analysis

The report provides insights into:

*
The report provides detailed insights into the key companies that are developing therapies in the Postoperative Pain Market.

*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Postoperative Pain treatment.

*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Postoperative Pain market.

Download our free sample report @ https://www.delveinsight.com/sample-request/postoperative-pain-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Postoperative Pain Companies

There are approx. 45+ key companies which are developing the therapies for Postoperative Pain. The companies which have their Postoperative Pain drug candidates in the most advanced stage, i.e. phase III include, Vivozon Pharmaceutical Inc.

DelveInsight's report covers around 22+ products under different phases of clinical development like

*
Late stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I) along with the details of

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

Postoperative Pain pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

*
Intravenous

*
Subcutaneous

*
Oral

*
Intramuscular

*
Tropical

Postoperative Pain Products have been categorized under various Molecule types such as

*
Monoclonal Antibody

*
Peptides

*
Polymer

*
Small molecule

*
Gene therapy

Download Sample Pages to Get an in-depth Assessment of the Emerging Postoperative Pain Therapies and Key Companies: Postoperative Pain Clinical Trials and advancements https://www.delveinsight.com/report-store/postoperative-pain-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Postoperative Pain Pipeline Therapeutic Assessment

- Postoperative Pain Assessment by Product Type

- Postoperative Pain By Stage

- Postoperative Pain Assessment by Route of Administration

- Postoperative Pain Assessment by Molecule Type

Download Postoperative Pain Sample report to know in detail about the Postoperative Pain treatment market @ Postoperative Pain Therapeutic Assessment https://www.delveinsight.com/sample-request/postoperative-pain-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Table of Content

1. Report Introduction

2. Executive Summary

3. Postoperative Pain Current Treatment Patterns

4. Postoperative Pain - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Postoperative Pain Late-Stage Products (Phase-III)

7. Postoperative Pain Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Postoperative Pain Discontinued Products

13. Postoperative Pain Product Profiles

14. Postoperative Pain Key Companies

15. Postoperative Pain Key Products

16. Dormant and Discontinued Products

17. Postoperative Pain Unmet Needs

18. Postoperative Pain Future Perspectives

19. Postoperative Pain Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Postoperative Pain Pipeline Reports Offerings: https://www.delveinsight.com/report-store/postoperative-pain-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=postoperative-pain-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-and-pipeline-analysis]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.